Chi-Med begins Phase III trial of fruquintinib for gastric cancer

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) began the Phase III FRUTIGA trial of fruquintinib (HMPL-013) as second-line

Read the full 173 word article

User Sign In